Holmium Laser Enucleation of the Prostate Robot-Assisted Simple Prostatectomy for Lower Urinary Tract Symptoms in Patients with Extremely Large Prostates ≥200 cc: A Comparative Analysis.

Robot-assisted simple prostatectomy (RASP) and holmium laser enucleation of the prostate (HoLEP) are both well-established, minimally invasive surgical treatment options for lower urinary tract symptoms caused by benign prostatic enlargement. We have reported the first comparative analysis of both techniques in patients with prostates of ≥200 cc. Between 2009 and 2020 a total of 53 patients with a prostate volume of ≥200 cc were surgically treated at OLV Hospital Aalst (Belgium): 31 underwent RASP and 22 underwent HoLEP. Preoperative and postoperative assessments included uroflowmetry with maximum urinary flow rate (Qmax) and postvoid residual volume (PVR), as well as the International Prostate Symptom Score (IPSS) and quality of life (IPSS-QoL). The complication rates were evaluated according to the Clavien-Dindo Classification. Patients treated with RASP had significantly larger prostate volumes compared with HoLEP (median 226 cc 204.5 cc,  = 0.004). After a median follow-up of 14 months, both groups showed a significant improvement in the maximum flow rate (+10.60 mL/s +10.70 mL/s,  = 0.724) and a reduction of the IPSS score (-12.50 -9,  = 0.246) as well as improvement of the QoL (-3 -3,  = 0.880). Median operative time was similar in both groups (150 minutes 132.5 minutes,  = 0.665). The amount of resected tissue was lower in the RASP group (134.5 g 180 g,  = 0.029) and there was no significant difference in postoperative prostate-specific antigen (1.2 ng/mL 0.8 ng/mL,  = 0.112). Despite a similar median catheterization time (3 days 2 days,  = 0.748), the median hospitalization time was shorter in the HoLEP group (4 days 3 days,  = 0.052). Complication rates were similar in both groups (32% 36%,  = 0.987). Our results suggest similar outcomes for RASP and HoLEP in patients with very large prostates ≥200 cc. These findings will require external validation at other high-volume centers.